I would think Borje would be near retirement. And I thought he had had teaching or valued education responsibilities also at MD Anderson in addition to his research- but a long significant career for decades focused in Leukaemias and AML particularly too.
I did not think Borje would have been involved directly in this work anymore. Surely he would though be very happy about RAC progress with Zantrene and this clear synergy in research for proof of concept for PET scans for detection of extra-medellary spread of AML leukaemia. (case history for acute and refractory to treatments leukaemias) Especially in Acute Myloid Leukaemia for which Zantrene has been past fully approved, & has known and recognised efficacy. This re shown in RAC recent trials and Sheba trials + past many historical trials .
Plus, from this .. ? whatever else may occur from this , with the MD Anderson Centre. *Note also- Sheba in Israel is also affiliated with MD Anderson Centre in the US.
This is actually really exciting & very good. Not surprising but is excellent to see happening and makes a lot of sense for RAC shareholders imo.
There is a lot to gain by RAC supporting the PET research trial — to show and identify EM AML where otherwise is not being detected in current routine medical diagnostics. (MRI, radiography, bloods) ** Got to be able to have an accepted testing/ diagnostic as standard to diagnose metastasised leukaemia early, or where has occurred.
And then also we need this identified accepted diagnostic process— to demonstrate regression of the cancers if treatment . eg *Zantrene is effective.. as shown in EM AML patients in the Sheba trials. EM AML trial first patient enrolment we are all hoping to be imminent in Australia But you must prove and show presence of the disease as well as effectiveness of specific treatment, demonstrably to the FDA (a big Pharmaceutical future owner of Zantrene would probably be driver- with ALL the extensive data from over 60 trials & all work RAC doing and have done with Zantrene in modern times again.) This collaboration is all of assistance & with Race Oncology involvement . Also launching us back into the international arena , the US in particular .
With treatment however and efficacy- accepted best diagnosis as standard (PET scan) needs to be demonstrated irrefutably for KOLs ( Key opinion leaders- leading doctors in specific medical fields ) . * So that they are able to give definite cancer diagnostic and treatment guidelines ultimately propagated through the NCCN. (US National Cancer Committees network, NCCN. And there are a number of core committees administered by fulltime researchers and workers, convened regularly with meetings together of the leading doctors on the committees as well as health region representatives from across America - the main ? 30 maybe health and medical centres including MD Anderson , also represented in each committee. NCCN individual committees, all the members within — overview all the collated data presented and vote to make changes to current procedures and make recommendations for guidelines in care- for hospitals and administrative centres to adhere to. NCCN is separate to the FDA .
So for cancer —there are individual committees which form guidelines for which & if diagnostic procedures should be recommended as standard for specific cancers or risks to patients, including for survivorship post successful cancer treatments also. NCCN are determining guidelines for doctors or all hospitals and treatment & diagnostic centres - for approved treatments and diagnostics.
Obviously PET is already fully approved and known diagnostic care. PET doesn’t need to be approved or recognised as is a standard of care.
RAC have had complex legal processes re past trial work only published this year? - undertaken by MD Anderson Centre from ~ 2019 & very affirmative for Zantrene .
To diagnose EM AML - metastasised leukaemia early or where has occurred, we need for PET to be identified as should be accepted diagnostic procedure , not only for determining very serious cancer treatment as the cancer is dire and has spread into organs and bone — but also ** to especially also demonstrate regression or efficacy with cancers if treatment is effective. ie. to show Zantrene effectiveness or demonstrate clinical response to Zantrene and other treatments.
PET - first prove the concept that PER scan is best screening diagnostic, and indeed otherwise is missed diagnosis of extra-medellary spread (EM AML) . And therefore PET should be utilised for reliable detection, and of course the consequences if not diagnosed, death of the patient through not being detected.
Then show later-** can prove effect of the oncology treatment.
We all know or believe Zantrene compelling effectiveness and efficacy with AML, but also very important Zantrene can bring remissions in the impossible to treat cases , where EM progression. But you must hit the FDA with this( FDA have indicated RAC can progress to trial in the US with minimal additional consultation now- they have all past data and these past years work with RAC.
PET diagnosis for detection EM AML/Leukaemia, or cancers , eg prostate or breast etc too will also be true.
But here with EM AML- need make it irrefutable for KOLs ( Key opinion leaders- leading doctors in specific medical fields ) to be able to give definitive cancer diagnostic and treatment guidelines, ultimately through the NCCN (US National Cancer Committees network, there are a number of core committees administered by fulltime researchers and workers and convened regularly with doctors & health region representative in each committee, to overview data and vote and make changes to current procedures and make recommendations for guidelines in care for hospitals and administrative centres to adhere to )
RAC have had complex legal processes re past trial work only published this year? - undertaken by MD Anderson Centre from ~ 2019 & very affirmative for Zantrene . (posting before losing - hopefully of use, explain more of relationship and importance MD Anderson + very cost effective cooperation validating PET for diagnosis EM AML- for which Race Oncology current and planner upcoming trials globally as treatment for EM AML. Routine diagnosis of EM cancer if has occurred , needs to be standard)
(20min delay)